Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (ritonavir, atazanavir, emtricitabine, tenofovir)

Andrea Chiricozzi, Rosita Saraceno, Maria Vittoria Cannizzaro, Steven P. Nisticò, Sergio Chimenti, Alessandro Giunta

Research output: Contribution to journalArticle

Abstract

Background: Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide population, and it may worsen with HIV or be detected as HIV cutaneous manifestation. HIV-related psoriasis shows a severe and prolonged clinical course with more frequent exacerbations. The management of this condition is challenging because im-munomodulating and immunosuppressant agents may have variable and partial efficacy, and therefore, antiretroviral treatment represents a potential adjunctive therapeutic option. Results: In the case we report, the HIV test was shown to be crucial for driving the therapeutic approach. Indeed, antiretroviral agents have been proven to be effective in the treatment of HIV+ psoriasis as first-line therapy. Conclusion: The HIV test should be considered in high-risk patients affected by severe psoriasis and resistant to conventional and biological treatments. Copyright © 2012 S. Karger AG, Base.
Original languageEnglish
Pages (from-to)333-337
Number of pages5
JournalDermatology
Volume225
DOIs
Publication statusPublished - 2013

Keywords

  • Anti-tumor necrosis factor-α agent
  • Hepatitis C virus
  • Highly active antiretroviral therapy
  • Human immunodeficiency virus
  • Psoriasis

Fingerprint

Dive into the research topics of 'Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (ritonavir, atazanavir, emtricitabine, tenofovir)'. Together they form a unique fingerprint.

Cite this